Who
Jayson Rieger
CEO and President
Company insider
Files Form 4 as: CEO and President, Verrica Pharmaceuticals.
In numbers
- Trades disclosed
- 14
- Buys
- 4
- Sells
- 0
- Bought
- $651K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Nov 2024
- Last trade
- 17 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 18 Aug 2026 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K5,000 at $4.91 | filing |
| 17 Aug 2026filed 18 Aug 2026 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K5,000 at $4.91 | filing |
| 14 Aug 2026filed 18 Aug 2026 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $101K20,000 at $5.06 | filing |
| 14 Aug 2026filed 18 Aug 2026 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $101K20,000 at $5.06 | filing |
| 5 Jun 2026filed 9 Jun 2026 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —512,269 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —512,269 at $0.00 | filing |
| 25 Nov 2025filed 25 Nov 2025 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —23,577 | filing |
| 25 Nov 2025filed 25 Nov 2025 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $400K94,311 at $4.24 | filing |
| 14 Mar 2025filed 18 Mar 2025 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —850,000 at $0.00 | filing |
| 26 Nov 2024filed 26 Nov 2024 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 22 Nov 2024filed 26 Nov 2024 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —140,449 | filing |
| 22 Nov 2024filed 26 Nov 2024 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —140,449 | filing |
| 22 Nov 2024filed 26 Nov 2024 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | —280,898 | filing |
| 6 Nov 2024filed 6 Nov 2024 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000,000 at $0.00 | filing |
News
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit FacilityVRCA · manilatimes.net · 22 Oct 2026
0 headlines in the last 90 days name Jayson Rieger; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.